Obstipation is defined as “extreme” constipation, meaning practically an interruption of the gastrointestinal transit. Acute obstipation may arise de novo or may complicate an already chronic state of constipation. Obstipation in cancer patients may be due to the mechanical or metabolic effect of the tumor, may result from the use of antineoplastic drugs or of other drugs, or may be due to unrelated causes. Table 1 summarizes the causes of obstipation that arises in cancer patients.


Multiple Endocrine Neoplasia Type Ricinoleic Acid Salmon Calcitonin Colonic Obstruction Cauda Equina Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lo AM, Evans WE, Carey LC: Review of small bowel obstruction at Milwaukee County General Hospital. Am J Surg 111: 884, 1966.PubMedCrossRefGoogle Scholar
  2. 2.
    Sise JG, Crichlow RW: Obstruction due to malignant tumors. Semin Oncol 5: 213–224, 1978.PubMedGoogle Scholar
  3. 3.
    McNeil JE: Mechanism of obstruction in carcinoid tumors of the small intestine. Am J Clin Pathol 56: 452, 1971.Google Scholar
  4. 4.
    Glass RL, Le Duc RJ: Small intestinal obstruction from peritoneal carcinomatosis. Am J Surg 125: 316, 1973.PubMedCrossRefGoogle Scholar
  5. 5.
    Ulin AW, Delement FA, James PM: Large bowel obstruction due to carcinoma. Am Fam Physician 3: 79, 1971.PubMedGoogle Scholar
  6. 6.
    Glenn F, McSherry CK: Obstruction and perforation in colorectal cancer. Ann Surg 173: 983, 1971.PubMedCrossRefGoogle Scholar
  7. 7.
    Welsch JP, Donaldson GA: Management of severe obstruction of the large bowel due to malignant disease. Am J Surg 127: 492, 1974.CrossRefGoogle Scholar
  8. 8.
    Thurtle OA, Allen AP, Walters MT, Kitchen JV, Smith CL, Cawley MD: Intractable constipation in malignant phaeochromocytoma: Combined treatment with adrenergic blockade and cholinergic drugs. J R Soc Med 77: 327–328, 1984.PubMedGoogle Scholar
  9. 9.
    Short IA, Padfield PL: Malignant pheochromocytoma with severe constipation and myocardial necrosis. Br Med J 20: 793–794, 1976.CrossRefGoogle Scholar
  10. 10.
    Hume DM: Pheochromocytoma in the adult and in the child. Am J Surg 99: 458–496, 1960.PubMedCrossRefGoogle Scholar
  11. 11.
    Cuthberg JA, Gallagher ND, Turtle JR: Colonic and oesophageal disturbance in a patient with multiple endocrine neoplasia, type IIb. Aust N Z Med 8: 518–520, 1978.CrossRefGoogle Scholar
  12. 12.
    Posner JB: Neurological complications of systemic cancer. Med Clin North Am 63: 783–800, 1979.PubMedGoogle Scholar
  13. 13.
    Veith RG, Odom GL: Extradural spinal metastases and their neurosurgical treatment. J Neurosurg 23: 501–508, 1965.CrossRefGoogle Scholar
  14. 14.
    Arseni CN, Simionescu MD, Horwath L: Tumors of the spine: A follow-up study of 350 patients with neurosurgical considerations. Acta Psychiatr Scand 34: 398–410, 1959.PubMedCrossRefGoogle Scholar
  15. 15.
    Rodriguez M, Dinapoli RP: Spinal cord compression with special reference to metastatic epidural tumors. Mayo Clin Proc 55: 442–448, 1980.PubMedGoogle Scholar
  16. 16.
    Petursson SR, Boggs DR: Spinal cord involvement in leukemia: A review of the literature and a case of Ph’ + acute myeloid leukemia presenting with a tonus medullaris syndrome. Cancer 47: 346–350, 1981.PubMedCrossRefGoogle Scholar
  17. 17.
    Olsen CW: Leukemia as a cause of cauda equina syndrome. Bull Los Angeles Neurol Soc 1: 9598, 1935.Google Scholar
  18. 18.
    Gilbert RW, Kim JH, Posner JB: Epidural spinal cord compression from metastatic tumor: Diagnosis and treatment. Ann Neurol 3: 40–51, 1978.PubMedCrossRefGoogle Scholar
  19. 19.
    Silvis RS, Riddle LR, Clark GG: Anterior sacral meningocele. Am Surg 22: 554–566, 1956.PubMedGoogle Scholar
  20. 20.
    Anderson FM, Burke BL: Anterior sacral meningocele. J Am Med Assoc 237: 39–42, 1977.CrossRefGoogle Scholar
  21. 21.
    Fields AL, Josee RG, Bergsagel DE: Metabolic emergencies, in De Vita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Toronto, JB Lippincott, 1982, pp 1594–1604.Google Scholar
  22. 22.
    Mundy GR, Martin TJ: Hypercalcemia of malignancy: Pathogenesis and treatment. Metabolism 31: 1247–1277, 1982.PubMedCrossRefGoogle Scholar
  23. 23.
    Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE: Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Eng J Med 291: 1041–1046, 1974.CrossRefGoogle Scholar
  24. 24.
    Raisz LG, Simmons HA, Sandberg AL, Canalis E: Direct stimulation of bone resorption by epidermal growth factor. Endocrinology 107: 270–273, 1980.PubMedCrossRefGoogle Scholar
  25. 25.
    Fillastre JP, Humbert G, Leroy J, et al: Furosemide, mithramycin and salmon calcitonin in hypercalcemia. Eur J Intensive Care Med 1: 185, 1975.CrossRefGoogle Scholar
  26. 26.
    Boyle IT, Foeglman I: Glucocorticoids and estrogens in the management of hypercalcemia. Met Bone Dis Rel Res 2: 203, 1980.CrossRefGoogle Scholar
  27. 27.
    Mannheimer IH: Hypercalcemia of breast cancer. Cancer 18: 679, 1965.PubMedCrossRefGoogle Scholar
  28. 28.
    Slayton RE, Shnider BI, Elias E, et al: New approaches to the treatment of hypercalcemia: The effect of short-term treatment with mithramycin. Clin Pharmacol Ther 12: 833, 1971.PubMedGoogle Scholar
  29. 29.
    Binstock ML, Mundy GR: Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med 93: 269, 1980.PubMedCrossRefGoogle Scholar
  30. 30.
    Wisneski LA, Croom WP, Silva OK, et al: Salmon calcitonin in hypercalcemia. Clin Pharmacol Ther 24: 219, 1978.PubMedGoogle Scholar
  31. 31.
    Jaffe JH, Martin WR: Opioid analgesics and antagonists, in Goodman-Gilman A, Goodman LS, Gilman A (eds): The Pharmacological Basis of Therapeutics, 6th ed. New York, Macmillan, 1980, pp 494–534.Google Scholar
  32. 32.
    Valdivieso M, Richman S, Burgess AM, Bodey DP, Freireich EJ: Initial clinical studies of vindesine. Cancer Treatment Rep 65: 873–875, 1981.Google Scholar
  33. 33.
    Neely J, Catchpole B: Ileus: The restoration of alimentary mobility by pharmacological means. Br J Surg 58: 21, 1971.PubMedCrossRefGoogle Scholar
  34. 34.
    Binder MJ, Donowitz M: A new look at laxative action. Gastroenterology 69: 1001–1005, 1975.PubMedGoogle Scholar
  35. 35.
    Pietruski RG: Use and abuse of laxatives. AM J Hosp Pharm 34: 291–300, 1977.Google Scholar
  36. 36.
    Stewart JY, Bass P: Effects of ricinoleic and oleic acids on the digestive contractile activity of the canine small and large bowel. Gastroenterology 70: 371–376, 1976.PubMedGoogle Scholar
  37. 37.
    Garginella TS, Phillips SF: Ricinoleic acid (castor oil) alters intestinal surface structure. Mayo Clin Proc 51: 6–12, 1976.Google Scholar
  38. 38.
    Hardcastle JD, Wilkins JL: The action of semnosides and related compounds on human colon and rectum. Gut 11: 1038–1042, 1970.PubMedCrossRefGoogle Scholar
  39. 39.
    Knowles JA: Effects on the infant of drug therapy in nursing mothers. Drug Ther 3: 57–65, 1973.Google Scholar
  40. 40.
    Sterr HW, Colin-Jones DG: Melanosis coli: Studies of the toxic effects of irritant purgatives. J Pathol 115: 199–205, 1975.CrossRefGoogle Scholar
  41. 41.
    Donovitz M: Current concepts of laxative action: Mechanisms by which laxatives increase stool water. Gastroenterology 1: 77–84, 1979.Google Scholar
  42. 42.
    Mordeo JP, Schwartz R, Arky RA: Extreme hypermagnesemia as a cause of refractory hypotension. Ann Intern Med 83: 657–658, 1975.CrossRefGoogle Scholar
  43. 43.
    Tedesco FJ, DiPiro JT: Laxative use in constipation. Am J Gastroenterol 80: 303–309, 1985.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Niculae Ciobanu
    • 1
  1. 1.Department of OncologyAlbert Einstein College of Medicine/Montefiore Medical CenterBronxUSA

Personalised recommendations